JP2001503055A - 置換三環化合物群 - Google Patents

置換三環化合物群

Info

Publication number
JP2001503055A
JP2001503055A JP10520585A JP52058598A JP2001503055A JP 2001503055 A JP2001503055 A JP 2001503055A JP 10520585 A JP10520585 A JP 10520585A JP 52058598 A JP52058598 A JP 52058598A JP 2001503055 A JP2001503055 A JP 2001503055A
Authority
JP
Japan
Prior art keywords
arthritis
alkyl
phenyl
compound
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10520585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503055A5 (https=
Inventor
バック，ニコラス・ジェイ
ディラード，ロバート・ディ
ドラハイム，スーザン・イー
モリン，ジョン・エム・ジュニア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2001503055A publication Critical patent/JP2001503055A/ja
Publication of JP2001503055A5 publication Critical patent/JP2001503055A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP10520585A 1996-10-30 1997-10-23 置換三環化合物群 Pending JP2001503055A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2984996P 1996-10-30 1996-10-30
US60/029,849 1996-10-30
PCT/US1997/019183 WO1998018464A1 (en) 1996-10-30 1997-10-23 Substituted tricyclics

Publications (2)

Publication Number Publication Date
JP2001503055A true JP2001503055A (ja) 2001-03-06
JP2001503055A5 JP2001503055A5 (https=) 2009-09-17

Family

ID=21851210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10520585A Pending JP2001503055A (ja) 1996-10-30 1997-10-23 置換三環化合物群

Country Status (26)

Country Link
EP (1) EP0839806B1 (https=)
JP (1) JP2001503055A (https=)
KR (1) KR20000049210A (https=)
CN (1) CN1233176A (https=)
AR (1) AR010050A1 (https=)
AT (1) ATE244703T1 (https=)
AU (1) AU734096B2 (https=)
BR (1) BR9713261A (https=)
CA (1) CA2269203A1 (https=)
CO (1) CO4920250A1 (https=)
CZ (1) CZ136899A3 (https=)
DE (1) DE69723393T2 (https=)
DK (1) DK0839806T3 (https=)
EA (1) EA003992B1 (https=)
ES (1) ES2202560T3 (https=)
ID (1) ID18685A (https=)
IL (1) IL129481A0 (https=)
NO (1) NO314899B1 (https=)
NZ (1) NZ335246A (https=)
PE (1) PE10999A1 (https=)
PL (1) PL332896A1 (https=)
PT (1) PT839806E (https=)
TR (1) TR199900956T2 (https=)
TW (1) TW513428B (https=)
WO (1) WO1998018464A1 (https=)
YU (1) YU19299A (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11322713A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物
JPH11322745A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物およびそれを含有する組成物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
HUP0102981A3 (en) 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
BR9910095A (pt) 1998-05-01 2000-12-26 Lilly Co Eli Compostos inibidores de spla2 para tratamento de doença
WO1999059999A1 (en) 1998-05-21 1999-11-25 Shionogi & Co., Ltd. PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES HAVING sPLA2 INHIBITORY EFFECT
AU6004799A (en) 1998-10-14 2000-05-01 Shionogi & Co., Ltd. Remedies or preventives for ischemic reflow failure
US6448284B1 (en) * 1998-12-22 2002-09-10 Eli Lilly And Company Substituted tricyclics
AU6015600A (en) 1999-07-19 2001-02-05 Shionogi & Co., Ltd. Tricyclic compounds having spla2-inhibitory activities
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
WO2001014378A1 (en) 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6756376B1 (en) 1999-11-15 2004-06-29 Shionogi & Co., Ltd. Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
JP2003519198A (ja) * 2000-01-06 2003-06-17 イーライ・リリー・アンド・カンパニー 炎症性疾患および呼吸器疾患の処置のための併用療法
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
WO2002000621A1 (en) 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
TWI314457B (https=) * 2001-03-19 2009-09-11 Shionogi & Co
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
WO2006046779A1 (ja) 2004-10-29 2006-05-04 Zeria Pharmaceutical Co., Ltd. カルバゾール誘導体、その溶媒和物、又は薬学的に許容されるその塩
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
CN112409493B (zh) * 2020-08-12 2022-09-30 浙江工业大学 一种重组融合酶及其在乙醛酸甲酯合成中的应用
US12208031B2 (en) 2020-10-21 2025-01-28 Purewick Corporation Adapters for fluid collection devices
US12440370B2 (en) 2020-10-21 2025-10-14 Purewick Corporation Apparatus with compressible casing for receiving discharged urine
US12257174B2 (en) 2020-10-21 2025-03-25 Purewick Corporation Fluid collection assemblies including at least one of a protrusion or at least one expandable material

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3479391A (en) * 1966-10-03 1969-11-18 Squibb & Sons Inc Delta**3,14-17alpha-hydroxy-norprogesterone and esters
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11322713A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物
JPH11322745A (ja) * 1998-04-17 1999-11-24 Eli Lilly & Co 置換三環式化合物およびそれを含有する組成物
JP2000026416A (ja) * 1998-04-17 2000-01-25 Eli Lilly & Co 置換された三環式化合物

Also Published As

Publication number Publication date
DE69723393T2 (de) 2004-06-09
DK0839806T3 (da) 2003-10-27
EP0839806A1 (en) 1998-05-06
EA003992B1 (ru) 2003-12-25
CN1233176A (zh) 1999-10-27
EP0839806B1 (en) 2003-07-09
BR9713261A (pt) 2000-03-28
NO314899B1 (no) 2003-06-10
AU5149498A (en) 1998-05-22
YU19299A (sh) 2000-03-21
DE69723393D1 (de) 2003-08-14
AR010050A1 (es) 2000-05-17
CA2269203A1 (en) 1998-05-07
CZ136899A3 (cs) 1999-09-15
ID18685A (id) 1998-04-30
EA199900305A1 (ru) 1999-12-29
ATE244703T1 (de) 2003-07-15
AU734096B2 (en) 2001-06-07
TR199900956T2 (xx) 1999-07-21
WO1998018464A1 (en) 1998-05-07
NZ335246A (en) 2001-09-28
TW513428B (en) 2002-12-11
CO4920250A1 (es) 2000-05-29
PL332896A1 (en) 1999-10-25
PE10999A1 (es) 1999-02-10
NO991831L (no) 1999-06-21
ES2202560T3 (es) 2004-04-01
NO991831D0 (no) 1999-04-16
KR20000049210A (ko) 2000-07-25
IL129481A0 (en) 2000-02-29
PT839806E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
JP2001503055A (ja) 置換三環化合物群
JP4435330B2 (ja) 置換された三環式化合物
JP2001503055A5 (https=)
US6177440B1 (en) Substituted tricyclics
JP2001522884A (ja) アルツハイマー病の処置方法
JP4435325B2 (ja) 置換三環式化合物およびそれを含有する組成物
US6713645B1 (en) Substituted tricyclics
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
EP1140943B1 (en) Substituted pyrroloindoles
JP2000502083A (ja) ｓＰＬＡ▲下２▼インヒビターとしてのナフチルグリオキサミド類
EP0640612B1 (fr) Nouveaux dérivés de 2-(1H)-quinoléinone, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
HK1010546A (en) Substituted tricyclics
HUP9903545A2 (hu) Helyettesített triciklusos vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
HK1024912A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041025

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081114

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090205

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090703